Recurrent rhabdomyolysis in a patient with oculocutaneous albinism type 1 and platelet storage‐pool deficiency

Oculocutaneous albinism type 1; platelet storage-pool deficiency; Hermansky-Pudlak syndrome;recurrent rhabdomyolysis; malignant hyperthermia syndromeOculocutaneous albinism (OCA) comprises a group of autosomal recessive disorders with aclinical spectrum that ranges from the most severe OCA type 1A (OCA1A, OMIM 203100),with a complete lack of melanin production throughout life, to milder forms (OCA1B,OMIM 606952; OCA2, OMIM 203200; OCA3, OMIM 203290; and OCA4, OMIM606574) [Gronskov, 2007]. At least four human genes are implicated; TYR, P, TYRP1andMATP. There are also syndromic forms of OCA, among which is Hermansky-Pudlaksyndrome (HPS, OMIM 203300), an autosomal recessive disease characterized by OCA,bleeding tendency due to platelet storage-pool deficiency, and variable manifestations due tolysosomal ceroid lipofuscinosis in multiple organs. [Wei, 2006; Huizing and Gahl, 2002;Gahl et al., 1998; Li et al., 2003]. The clinical manifestations of different HPS types arevariable and at least 8 human types have been described associated with mutations in 4ubiquitously expressed protein complexes genes; adaptor protein-3 (AP-3) and biogenesis oflysosome-related organelles complex 1 through -3 (BLOC-1,-2 and -3) [Dell’Angelica,2004].Here we present a patient with oculocutaneous albinism type 1, recurrent rhabdomyolysisand bleeding diathesis. Our patient (Fig. 1A) was a 14.5 year old girl from Corfu island(Greece), born at term to healthy, nonconsanguineous parents. She had oculocutaneousalbinism, horizontal nystagmus, photophobia and severely decreased visual acuity. Her

[1]  Karen Brondum-Nielsen,et al.  Oculocutaneous albinism , 2007, Orphanet journal of rare diseases.

[2]  R. Nazarian,et al.  Reinvestigation of the dysbindin subunit of BLOC-1 (biogenesis of lysosome-related organelles complex-1) as a dystrobrevin-binding protein. , 2006, The Biochemical journal.

[3]  Maria L. Wei Hermansky-Pudlak syndrome: a disease of protein trafficking and organelle function. , 2006, Pigment cell research.

[4]  Colin A. Johnson,et al.  A germline mutation in BLOC1S3/reduced pigmentation causes a novel variant of Hermansky-Pudlak syndrome (HPS8). , 2006, American journal of human genetics.

[5]  E. C. Dell'Angelica,et al.  The building BLOC(k)s of lysosomes and related organelles. , 2004, Current opinion in cell biology.

[6]  R. Swank,et al.  Murine Hermansky–Pudlak syndrome genes: regulators of lysosome‐related organelles , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[7]  M. Brilliant,et al.  P gene mutations in patients with oculocutaneous albinism and findings suggestive of Hermansky-Pudlak syndrome , 2004, Journal of Medical Genetics.

[8]  D. Blake,et al.  Myospryn Is a Novel Binding Partner for Dysbindin in Muscle* , 2004, Journal of Biological Chemistry.

[9]  C. Summers,et al.  Tyrosinase gene mutations in oculocutaneous albinism 1 (OCA1): definition of the phenotype , 2003, Human Genetics.

[10]  Naoki Oiso,et al.  Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosome-related organelles complex 1 (BLOC-1) , 2003, Nature Genetics.

[11]  M. Huizing,et al.  Disorders of vesicles of lysosomal lineage: the Hermansky-Pudlak syndromes. , 2002, Current molecular medicine.

[12]  W. Gahl,et al.  Nonsense Mutations in ADTB3A Cause Complete Deficiency of the β3A Subunit of Adaptor Complex-3 and Severe Hermansky-Pudlak Syndrome Type 2 , 2002, Pediatric Research.

[13]  F. Muntoni,et al.  A severe clinical and pathological variant of central core disease with possible autosomal recessive inheritance , 1998, Neuromuscular Disorders.

[14]  E. Kuehl,et al.  Genetic defects and clinical characteristics of patients with a form of oculocutaneous albinism (Hermansky-Pudlak syndrome). , 1998, The New England journal of medicine.

[15]  M. Phillips,et al.  The structural organization of the human skeletal muscle ryanodine receptor (RYR1) gene. , 1996, Genomics.

[16]  C. Doriguzzi,et al.  Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia , 1993, Nature Genetics.

[17]  H. Jungbluth Orphanet Journal of Rare Diseases BioMed Central Review Central core disease , 2007 .

[18]  Beverley McNeil,et al.  Malignant Hyperthermia , 2005, Springer US.